FDA asks for more Gadolite information:
This article was originally published in Clinica
Executive Summary
The FDA has asked for more information on Gadolite oral suspension, which is currently awaiting approval for use in bowel imaging. The request was made in an approvable letter to manufacturer Pharmacyclics. E-Z-EM recently began selling the agent in the UK, following approval by the Medicines Control Agency (see Clinica No 736/7, p 16). E-Z-EM also has marketing rights for the US, Mexico and Canada.
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.